Town & Country Bank & Trust CO dba First Bankers Trust CO decreased its stake in Stryker Co. (NYSE:SYK – Free Report) by 10.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,100 shares of the medical technology company’s stock after selling 130 shares during the period. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in Stryker were worth $336,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Tsfg LLC lifted its stake in Stryker by 39.8% in the 2nd quarter. Tsfg LLC now owns 123 shares of the medical technology company’s stock valued at $38,000 after purchasing an additional 35 shares during the last quarter. Stratos Wealth Advisors LLC raised its stake in shares of Stryker by 1.0% during the first quarter. Stratos Wealth Advisors LLC now owns 3,632 shares of the medical technology company’s stock valued at $1,037,000 after acquiring an additional 37 shares during the last quarter. Perigon Wealth Management LLC raised its stake in shares of Stryker by 1.5% during the first quarter. Perigon Wealth Management LLC now owns 2,500 shares of the medical technology company’s stock valued at $714,000 after acquiring an additional 37 shares during the last quarter. Ameritas Advisory Services LLC raised its stake in shares of Stryker by 2.4% during the fourth quarter. Ameritas Advisory Services LLC now owns 1,609 shares of the medical technology company’s stock valued at $393,000 after acquiring an additional 38 shares during the last quarter. Finally, Putnam Investments LLC raised its stake in shares of Stryker by 3.3% during the first quarter. Putnam Investments LLC now owns 1,222 shares of the medical technology company’s stock valued at $349,000 after acquiring an additional 39 shares during the last quarter. Institutional investors own 76.24% of the company’s stock.
Stryker Stock Down 0.8 %
NYSE:SYK traded down $2.23 during trading hours on Friday, reaching $292.77. The company had a trading volume of 2,134,362 shares, compared to its average volume of 1,095,935. The company has a quick ratio of 0.84, a current ratio of 1.54 and a debt-to-equity ratio of 0.64. The firm has a market cap of $111.19 billion, a price-to-earnings ratio of 41.35, a P/E/G ratio of 2.85 and a beta of 0.95. The business’s 50-day simple moving average is $286.90 and its two-hundred day simple moving average is $285.73. Stryker Co. has a twelve month low of $200.80 and a twelve month high of $306.93.
Stryker Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 31st. Stockholders of record on Friday, September 29th will be issued a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.02%. The ex-dividend date is Thursday, September 28th. Stryker’s dividend payout ratio is currently 42.37%.
In other news, insider Viju Menon sold 5,000 shares of Stryker stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $289.00, for a total transaction of $1,445,000.00. Following the completion of the transaction, the insider now directly owns 6,994 shares in the company, valued at $2,021,266. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 5.90% of the company’s stock.
Wall Street Analyst Weigh In
SYK has been the subject of several analyst reports. Barclays raised their price target on shares of Stryker from $321.00 to $335.00 and gave the company an “overweight” rating in a research note on Monday, August 7th. StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research note on Friday, September 8th. Bank of America raised shares of Stryker from a “neutral” rating to a “buy” rating and raised their price target for the company from $310.00 to $315.00 in a research note on Tuesday, September 5th. BTIG Research increased their price objective on shares of Stryker from $313.00 to $331.00 in a research report on Monday, July 17th. Finally, Morgan Stanley increased their price objective on shares of Stryker from $295.00 to $300.00 and gave the stock an “equal weight” rating in a research report on Monday, August 7th. Six equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus price target of $309.59.
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.
- Five stocks we like better than Stryker
- How to Invest in Growth Stocks
- 5 Reasons Apple’s New Phone Moves the Needle: 5 That It Won’t
- Consumer Staples Stocks, Explained
- MarketBeat Week in Review – 9/11 – 9/15
- How to Invest in Social Media
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.